Two faces of Hippo: activate or suppress the Hippo pathway in cancerCao, Jingwen; Huang, WenlongAnti-Cancer Drugs: November 2017 - Volume 28 - Issue 10 - p 1079–1085 doi: 10.1097/CAD.0000000000000559 REVIEW ARTICLES Buy Abstract Author InformationAuthors Article MetricsMetrics The Hippo pathway has generated considerable interest in recent years because of its involvement in several key hallmarks of cancer progression and metastasis. Research on the Hippo signaling pathway in cancer has been used to determine the activity of yes-associated protein (YAP) in tumorigenesis and disease progression. Previous studies have shown that the Hippo pathway can be used as a target to inhibit YAP activity and is a viable treatment for cancer. However, more studies are required to further advance our understanding of the Hippo signaling pathway in cancer. It has been shown that knockout of serine/threonine-kinases LATS1/2 in the Hippo pathway suppresses cancer immunity in mice. In addition, suppression of the oncogene YAP could contribute toward cancer immune therapy. Therefore, regulation of Hippo signaling can be an attractive alternative strategy for cancer treatment. This review will provide a summary of currently known compounds that activate or suppress the Hippo pathway. School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China Correspondence to Wenlong Huang, PhD, China Pharmaceutical University, #24 TongJiaXiang, Gulou District, Nanjing 210009, China Tel: +86 258 327 1487; fax: +86 2583 271 512; e-mail: email@example.com Received June 26, 2017 Accepted August 17, 2017 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.